对于患有无形细胞增生症的儿童来说,有新的治疗方法
Ravi Savarirayan1, Julie Hoover-Fong2, Patrick Yap3
1Murdoch Children's Research Institute, Parkville, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia.
The Lancet. Child & adolescent health
|March 14, 2024
概括
形形成症是一种矮形状,是由影响FGFR3.3的遗传变异引起的. 新兴疗法现在正在改善这种疾病患者的生长模式和长期健康状况.
科学领域:
- 遗传学 遗传学 是一个
- 骨生物学 骨生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 无形质是最常见的骨发育不良症,其特点是内分泌骨骨化受损.
- 它是由纤维细胞生长因子受体3 (FGFR3) 基因的病原性变异引起的.
- 这种情况在整个生命周期中显著影响患者的健康和生活质量.
研究的目的:
- 审查阿德罗普拉西亚和相关的FGFR3条件的临床和遗传特征.
- 讨论自然史,诊断和阿德罗普拉西亚的管理.
- 突出针对阿德罗普拉西亚潜在分子机制的新型药物治疗方法.
主要方法:
- 临床研究,遗传分析和药物开发试验的文献综述.
- 综合了有关无粒细胞形成症的病理生理学和治疗环境的信息.
- 分析新兴的治疗策略及其潜在影响.
主要成果:
- 详细描述了阿德罗普拉西亚的遗传基础和临床表现.
- 目前的诊断和管理方法的概述.
- 确定修改FGFR3信号通路的新药疗法.
结论:
- 针对FGFR3的新兴疗法正在证明其有可能改变无形质生长的自然生长轨迹.
- 这些进步为患有骨质疏松症的个体提供了改善的长期健康结果.
- 持续的研究和临床试验对于优化治疗策略至关重要.
相关概念视频
01:27Fractures: Bone Repair
3.2K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
3.2K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164